Wells Fargo & Company Larimar Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 19,657 shares of LRMR stock, worth $46,390. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,657
Previous 12,956
51.72%
Holding current value
$46,390
Previous $84,000
10.71%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding LRMR
# of Institutions
124Shares Held
66.7MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$50.1 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$15.2 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$14.3 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$11 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$9.8 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $102M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...